EDIT - Editas Medicine Inc. (EDIT) Q1 2024 Earnings Call Transcript
2024-05-08 10:57:01 ET
Editas Medicine, Inc. (EDIT)
Q1 2024 Earnings Conference Call
May 08, 2024, 08:00 AM ET
Company Participants
Cristi Barnett - Corporate Communications and IR
Gilmore O'Neill - CEO
Baisong Mei - CMO
Erick Lucera - CFO
Linda Burkly - CSO
Caren Deardorf - Chief Commercial and Strategy Officer
Conference Call Participants
Samantha Semenkow - Citi
Joon Lee - Truist Securities
Mary Kate Davis - Bank of America
Jack Allen - Baird
Gena Wang - Barclays
Brian Cheng - JPMorgan
Eric Schmidt - Cantor Fitzgerald
Jay Olson - Oppenheimer & Company
Yanan Zhu - Wells Fargo
Luca Issi - RBC Capital
Mani Foroohar - Leerink Partners
Presentation
Operator
Good morning, and welcome to the Editas Medicine's First Quarter 2024 Conference Call. All participants are now in a listen-only mode. There will be a question-and-answer session at the end of this call. Please be advised that this call is being recorded at the company's request.
I would now like to turn the call over to Cristi Barnett, Corporate Communications and Investor Relations at Editas Medicine.
Cristi Barnett
Thank you. Good morning, everyone, and welcome to our first quarter 2024 conference call.
Earlier this morning, we issued a press release providing our financial results and recent corporate updates. A replay of today's call will be available in the Investors section of our website approximately two hours after its completion. After our prepared remarks, we will open the call for Q&A.
As a reminder, various remarks that we make during this call about the company's future expectations, plans and prospects constitute forward-looking statements for the purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our most recent Annual Report on Form 10-K, which is on file with the SEC as updated by our subsequent filings.
In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. Except as required by law, we specifically disclaim any obligation to update or revise any forward-looking statements, even if our views change....
Editas Medicine, Inc. (EDIT) Q1 2024 Earnings Call Transcript